WaveLight Inc. of Sterling, Va., has announced FDA approval of wavefront-guided and mixed astigmatism indications for the company’s Allegretto Wave Eye-Q lasik system. The wavefront-guided procedure was approved for the reduction or elimination of up to –7 diopters of spherical equivalent of myopia or of myopia with astigmatism. The Eye-Q mixed astigmatism procedure was approved for the reduction or elimination of naturally occurring mixed astigmatism of up to 6 diopters at the spectacle plane. In both cases, patients must meet age and condition requirements.